Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.87 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
94 95 Next >
Smart Money Is Betting Big In MRK Options
Via Benzinga
Peering Into Merck & Co's Recent Short Interest
Via Benzinga
2024 Marks a New Era Of Pharmaceutical Innovation
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned... 
Via Benzinga
Exposures COVID-19
Demystifying Merck & Co: Insights From 9 Analyst Reviews
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
P/E Ratio Insights for Merck & Co
Via Benzinga
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an  
Via Benzinga
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi 
Via Benzinga
Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics
Via Benzinga
Merck, the Dow's hottest stock, gets set to report Q4 financials
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks. 
Via MarketBeat
Topics Stocks
Exposures US Equities
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
The year's biggest medical conference kicked off with a melee of buyout news. 
Via Investor's Business Daily
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
Via Investor Brand Network
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
Shares shot 7% higher in the first week of 2024 as excitement grows for its late-stage pipeline. 
Via Investor's Business Daily
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?
Harpoon Therapeutics stock is rocketing higher on Monday as HARP investors react to Merck acquiring the company for $23 per share. 
Via InvestorPlace
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
From Merck & Co., Inc.
Via Business Wire
Why Is Cancer Focused Harpoon Therapeutics Stock Shooting Higher Today?
Merck & Co Inc (NYSE: MRK) is reportedly negotiating to purchase cancer drugmaker Harpoon Therapeutics Inc (NASDAQ:  
Via Benzinga
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
These four names span different sectors, but all underperformed in 2023. Is it time to be a contrarian and pick up bargains on the discount aisle? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Wall Street's Top 10 Stock Calls This Week - Saturday, Jan. 6
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Jan. 2-5. 
Via Talk Markets
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
Exposures Product Safety
Healthcare Champions Kick Off 2024
Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer upgraded the stock due to the Covid-19 vaccine star possibly... 
Via Benzinga
Exposures COVID-19
Dry January Investing: Trading Pints For Portfolio Growth
Around 15% of Americans said they were planning to participate in Dry January — a month of abstinence from alcohol — according to a survey. 
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
3 reasons 2024 Moderna shareholders may party like it's 2021
With interest in Moderna Inc. stock picking up alongside news flow, investors could be in for some very healthy 2024 gains. 
Via MarketBeat
Exposures COVID-19
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stocks Edge Higher, Nasdaq Looks To Snap Skid
Stocks are attempting to regain their 2023 form today. 
Via Talk Markets
McDonald's Revenues Expected To Increase, Plus Merck And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners named Merck & Co., Inc. (NYSE: MRK) 
Via Benzinga
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,... 
Via Benzinga
Topics ETFs
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
94 95 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.